Form 4: Plus Therapeutics Director Acquires Stock Options
SEC Form 4 Filing
Director Greg Petersen acquired stock options in Plus Therapeutics, Inc. on September 11, 2024.
Summary
- On September 11, 2024, Greg Petersen, a director of Plus Therapeutics, Inc., acquired 3,650 stock options.
- The options have an exercise price of $1.26.
- The options vest monthly over 12 months from the grant date or in full at the next annual meeting, contingent on continued service.
- The options expire on September 11, 2034.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing a transaction. It doesn't inherently convey positive or negative sentiment.
Future Outlook
The options vest monthly over 12 months from the grant date or in full at the next annual meeting, contingent on continued service.
Industry Context
This filing is a routine disclosure of a director's acquisition of stock options, a common form of executive compensation in publicly traded companies. It provides transparency to investors regarding the holdings of company insiders.
Stakeholder Impact
- The acquisition of stock options by a director can signal confidence in the company's future prospects to shareholders.
Key Dates
| Date | Description |
|---|---|
| 09/11/2024 | Date of transaction: Greg Petersen acquired stock options. |
| 09/11/2024 | Grant date of the stock options. |
| 09/11/2034 | Expiration date of the stock options. |
| 09/12/2024 | Date of signature on the Form 4 filing. |
Keywords
stock options, director, PSTV, Plus Therapeutics, Form 4, Greg Petersen, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.